NewzVille Desk
The 9th India Pharma 2026, the flagship event of the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, Government of India, commenced today in New Delhi. Organized in collaboration with the Federation of Indian Chambers of Commerce and Industry (FICCI) and the Indian Pharmaceutical Alliance (IPA), the two-day conference (13–14, April ) brings together key stakeholders from across the global pharmaceutical and healthcare ecosystem, with a strong focus on innovation, self-reliance, and global leadership.
Addressing the gathering virtually, Union Minister of Health & Family Welfare and Chemicals & Fertilizers,J.P. Nadda, emphasized that the platform reflects both the strength and growing global relevance of India’s pharmaceutical sector.
He noted that while India has long been recognized as the “pharmacy of the world” due to its leadership in affordable generic medicines, the global landscape is now rapidly shifting towards biologics, biosimilars, and specialty medicines. “In this evolving environment, India is well positioned not only to adapt but to emerge as a global leader,” he stated.
Minister of State for Health & Family Welfare and Chemicals & Fertilizers, Anupriya Patel, highlighted that India is undergoing a significant transition from being a global generics leader to an emerging biopharma innovation hub.
She noted that India currently contributes nearly 20% of global generic medicines and meets around 70% of global vaccine demand, underscoring the country’s robust manufacturing capabilities.
Emphasizing future opportunities, she stated that the global demand for biologics and biosimilars is expanding rapidly, with the biosimilars market projected to reach $75 billion by 2030.
She further pointed out that innovative drugs account for nearly 87% of the global pharmaceutical market value, underlining the need for India to intensify its focus on innovation-driven segments.
Manoj Joshi, Secretary, Department of Pharmaceuticals, stressed the need to accelerate innovation timelines, strengthen startup ecosystems, and build robust infrastructure for clinical trials and advanced research.
He highlighted the importance of enhanced funding mechanisms, closer industry-government collaboration, and development of skilled talent.
Punya Salila Srivastava, Secretary, Ministry of Health & Family Welfare, reiterated the Government’s commitment to strengthening the regulatory ecosystem and enabling innovation.
She noted that several measures have been undertaken to streamline approval processes and improve the ease of doing research, with the aim of transforming India from the “pharmacy of the world” to an “innovator for the world.”
Arjun Juneja, Chair, FICCI Pharma Committee and COO, Mankind Pharma, highlighted India’s strong pharmaceutical base, noting the presence of over 3,000 companies and more than 10,500 manufacturing facilities, including the highest number of USFDA-compliant plants outside the United States. He emphasized the need for deeper collaboration between Indian and global players to drive innovation-led growth.
Achin Gupta, Co-Chair, FICCI Pharma Committee and MD & Global CEO, Cipla Ltd, delivered the vote of thanks.
